Seeking Alpha
10 Aug 2026, 20:38 UTC · 14w ago
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
Impact · against what's priced in
AbCellera's release of Phase II top-line results for ABCL635 represents a material clinical milestone. The progress of a drug candidate into later-stage viability typically serves as a positive catalyst for biotech valuations.
- ABCL+0.50
No priced-in read yet





